409 related articles for article (PubMed ID: 10409442)
1. c-myc and chromosome 8 centromere studies of ovarian cancer by interphase FISH.
Wang ZR; Liu W; Smith ST; Parrish RS; Young SR
Exp Mol Pathol; 1999 Jun; 66(2):140-8. PubMed ID: 10409442
[TBL] [Abstract][Full Text] [Related]
2. HER-2/neu oncogene amplification in stage I and stage III ovarian papillary serous carcinoma.
Afify AM; Werness BA; Mark HF
Exp Mol Pathol; 1999 Jun; 66(2):163-9. PubMed ID: 10409445
[TBL] [Abstract][Full Text] [Related]
3. Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma.
Santin AD; Bellone S; Van Stedum S; Bushen W; Palmieri M; Siegel ER; De Las Casas LE; Roman JJ; Burnett A; Pecorelli S
Cancer; 2005 Oct; 104(7):1391-7. PubMed ID: 16116605
[TBL] [Abstract][Full Text] [Related]
4. Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization.
Persons DL; Borelli KA; Hsu PH
Mod Pathol; 1997 Jul; 10(7):720-7. PubMed ID: 9237184
[TBL] [Abstract][Full Text] [Related]
5. ERBB2 and chromosome 17 centromere studies of ovarian cancer by fluorescence in situ hybridization.
Young SR; Liu WH; Brock JA; Smith ST
Genes Chromosomes Cancer; 1996 Jun; 16(2):130-7. PubMed ID: 8818660
[TBL] [Abstract][Full Text] [Related]
6. Amplification of c-myc by fluorescence in situ hybridization in a population-based breast cancer tissue array.
Rummukainen JK; Salminen T; Lundin J; Kytölä S; Joensuu H; Isola JJ
Mod Pathol; 2001 Oct; 14(10):1030-5. PubMed ID: 11598174
[TBL] [Abstract][Full Text] [Related]
7. Relations of the c-myc gene and chromosome 8 in non-small cell lung cancer: analysis by fluorescence in situ hybridization.
Kubokura H; Tenjin T; Akiyama H; Koizumi K; Nishimura H; Yamamoto M; Tanaka S
Ann Thorac Cardiovasc Surg; 2001 Aug; 7(4):197-203. PubMed ID: 11578259
[TBL] [Abstract][Full Text] [Related]
8. Fluorescence in situ hybridization analysis of c-myc amplification in stage TNM prostate cancer in Japanese patients.
Sato H; Minei S; Hachiya T; Yoshida T; Takimoto Y
Int J Urol; 2006 Jun; 13(6):761-6. PubMed ID: 16834657
[TBL] [Abstract][Full Text] [Related]
9. Fluorescence in situ hybridization analysis of HER-2/neu, c-myc, and p53 in endometrial cancer.
Williams JA; Wang ZR; Parrish RS; Hazlett LJ; Smith ST; Young SR
Exp Mol Pathol; 1999 Dec; 67(3):135-43. PubMed ID: 10600396
[TBL] [Abstract][Full Text] [Related]
10. Identification of HER-2/neu oncogene amplification by fluorescence in situ hybridization in stage I endometrial carcinoma.
Riben MW; Malfetano JH; Nazeer T; Muraca PJ; Ambros RA; Ross JS
Mod Pathol; 1997 Aug; 10(8):823-31. PubMed ID: 9267826
[TBL] [Abstract][Full Text] [Related]
11. Interphase molecular cytogenetic analysis of epithelial ovarian carcinomas.
Persons DL; Hartmann LC; Herath JF; Borell TJ; Cliby WA; Keeney GL; Jenkins RB
Am J Pathol; 1993 Mar; 142(3):733-41. PubMed ID: 8096121
[TBL] [Abstract][Full Text] [Related]
12. Detection of Her2/neu, c-MYC and ZNF217 gene amplification during breast cancer progression using fluorescence in situ hybridization.
Shimada M; Imura J; Kozaki T; Fujimori T; Asakawa S; Shimizu N; Kawaguchi R
Oncol Rep; 2005 Apr; 13(4):633-41. PubMed ID: 15756435
[TBL] [Abstract][Full Text] [Related]
13. Amplification and overexpression of HER-2/neu (c-erbB2) in endometrial cancers: correlation with overall survival.
Saffari B; Jones LA; el-Naggar A; Felix JC; George J; Press MF
Cancer Res; 1995 Dec; 55(23):5693-8. PubMed ID: 7585656
[TBL] [Abstract][Full Text] [Related]
14. Her-2/neu expression and amplification in early stage ovarian surface epithelial neoplasms.
Wu Y; Soslow RA; Marshall DS; Leitao M; Chen B
Gynecol Oncol; 2004 Dec; 95(3):570-5. PubMed ID: 15581965
[TBL] [Abstract][Full Text] [Related]
15. Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization.
Isola J; Tanner M; Forsyth A; Cooke TG; Watters AD; Bartlett JM
Clin Cancer Res; 2004 Jul; 10(14):4793-8. PubMed ID: 15269154
[TBL] [Abstract][Full Text] [Related]
16. Characterization of the HER-2/neu oncogene by immunohistochemical and fluorescence in situ hybridization analysis in oral and oropharyngeal squamous cell carcinoma.
Khan AJ; King BL; Smith BD; Smith GL; DiGiovanna MP; Carter D; Haffty BG
Clin Cancer Res; 2002 Feb; 8(2):540-8. PubMed ID: 11839675
[TBL] [Abstract][Full Text] [Related]
17. Molecular-cytogenetic analysis of HER-2/neu gene in BRCA1-associated breast cancers.
Grushko TA; Blackwood MA; Schumm PL; Hagos FG; Adeyanju MO; Feldman MD; Sanders MO; Weber BL; Olopade OI
Cancer Res; 2002 Mar; 62(5):1481-8. PubMed ID: 11888924
[TBL] [Abstract][Full Text] [Related]
18. Fluorescence in situ hybridization study of HER-2/neu oncogene amplification in prostate cancer.
Mark HF; Feldman D; Das S; Kye H; Mark S; Sun CL; Samy M
Exp Mol Pathol; 1999 Jun; 66(2):170-8. PubMed ID: 10409446
[TBL] [Abstract][Full Text] [Related]
19. Chromosome 8 numerical aberration and C-MYC copy number gain in bladder cancer are linked to stage and grade.
Mahdy E; Pan Y; Wang N; Malmström PU; Ekman P; Bergerheim U
Anticancer Res; 2001; 21(5):3167-73. PubMed ID: 11848469
[TBL] [Abstract][Full Text] [Related]
20. Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization.
Jenkins RB; Qian J; Lieber MM; Bostwick DG
Cancer Res; 1997 Feb; 57(3):524-31. PubMed ID: 9012485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]